



Press Release |

TRIAL DATE SET FOR REMAINING CLAIMS AGAINST IBA BY LOMA LINDA UNIVERSITY MEDICAL CENTER AND OPTIVUS TECHNOLOGY, INC.

Embargo until 5:40 pm – December 21, 2006

Louvain-la-Neuve, Belgium, December 21, 2006 – IBA (Ion Beam Applications S.A.: Reuters IOBAAt.BR and Bloomberg IBAB.BB) announced today that a trial will start in Los Angeles, California on February 27, 2007 on the remaining claims asserted against IBA by Optivus Technology, Inc. (“Optivus”) and Loma Linda University Medical Center (“LLUMC”).

In November 2006, the Federal Circuit affirmed the summary judgments in favor of IBA on all patent issues and most of the non-patent issues, but remanded the case for trial on certain narrow issues of unfair competition that relate solely to the University of Florida procurement process that led to the selection of IBA to build the proton beam treatment center in Jacksonville, Florida. Also pursuant to an agreement reached among the parties in 2004, Optivus and LLUMC were permitted to revive three patent claims following the issuance of the Federal Circuit opinion. The trial before United States District Judge S. James Otero will therefore include this narrow unfair competition claim and these three patent claims and is expected to last two weeks.

IBA continues to maintain that it does not infringe any of the patents in suit and did not compete with Optivus unfairly in connection with the University of Florida contract matter.

ABOUT IBA

IBA delivers solutions of a unique precision in the fields of **cancer diagnosis and therapy**. The company also offers sterilization and ionization solutions to improve the hygiene and safety of everyday life. IBA is listed on the pan-European stock exchange EURONEXT, is integrated into the NextEconomy market segment and belongs to the BelMid index.

Website: <http://www.iba-worldwide.com>.

Contact

IBA

Paul-Emmanuel Goethals
Director, Corporate Business Development
& Investor Relations
Phone: +32 10 47 58 16
paul-emmanuel.goethals@iba-group.com